Rani Therapeutics Discloses Progress in Oral Obesity Treatment; Shares Surge Premarket

MT Newswires Live

Feb 06, 2025

Rani Therapeutics (RANI) said late Wednesday that new data from a preclinical study evaluating the oral delivery of semaglutide via the RaniPill, or RT-116, capsule demonstrated comparable "bioavailability, pharmacokinetics, and weight loss to subcutaneous administration."

The company said the new data adds to the "growing body of evidence" about RaniPill's potential to enable oral delivery of multiple obesity treatments. Shares jumped more than 42% in premarket activity Thursday.

The company plans to undertake a phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist. The obesity trial will begin this year in partnership with ProGen.

Rani said semaglutide is currently only available as a subcutaneous injection to treat obesity. Novo Nordisk markets the treatment under the brand name Wegovy in the US.

Price: 2.05, Change: +0.61, Percent Change: +42.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2509473902"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509473902\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509473902?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509473902","market":"sg","top_or_hot":-1,"title":"Rani Therapeutics Discloses Progress in Oral Obesity Treatment; Shares Surge Premarket","media":"MT Newswires Live","content":"<html><body><p> Rani <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RANI) said late Wednesday that new data from a preclinical study evaluating the oral delivery of semaglutide via the RaniPill, or RT-116, capsule demonstrated comparable \"bioavailability, pharmacokinetics, and weight loss to subcutaneous administration.\"</p><p>The company said the new data adds to the \"growing body of evidence\" about RaniPill's potential to enable oral delivery of multiple obesity treatments. Shares jumped more than 42% in premarket activity Thursday.</p><p>The company plans to undertake a phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist. The obesity trial will begin this year in partnership with ProGen.</p><p>Rani said semaglutide is currently only available as a subcutaneous injection to treat obesity. Novo Nordisk markets the treatment under the brand name Wegovy in the US.</p><p>Price: 2.05, Change: +0.61, Percent Change: +42.36</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rani Therapeutics Discloses Progress in Oral Obesity Treatment; Shares Surge Premarket</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRani Therapeutics Discloses Progress in Oral Obesity Treatment; Shares Surge Premarket\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-06 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Rani <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RANI) said late Wednesday that new data from a preclinical study evaluating the oral delivery of semaglutide via the RaniPill, or RT-116, capsule demonstrated comparable \"bioavailability, pharmacokinetics, and weight loss to subcutaneous administration.\"</p><p>The company said the new data adds to the \"growing body of evidence\" about RaniPill's potential to enable oral delivery of multiple obesity treatments. Shares jumped more than 42% in premarket activity Thursday.</p><p>The company plans to undertake a phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist. The obesity trial will begin this year in partnership with ProGen.</p><p>Rani said semaglutide is currently only available as a subcutaneous injection to treat obesity. Novo Nordisk markets the treatment under the brand name Wegovy in the US.</p><p>Price: 2.05, Change: +0.61, Percent Change: +42.36</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509473902","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509473902","pubTimestamp":1738834489,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rani Therapeutics  said late Wednesday that new data from a preclinical study evaluating the oral delivery of semaglutide via the RaniPill, or RT-116, capsule demonstrated comparable \"bioavailability, pharmacokinetics, and weight loss to subcutaneous administration.\"The company said the new data adds to the \"growing body of evidence\" about RaniPill's potential to enable oral delivery of multiple obesity treatments. Shares jumped more than 42% in premarket activity Thursday.The company plans to undertake a phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist. The obesity trial will begin this year in partnership with ProGen.Rani said semaglutide is currently only available as a subcutaneous injection to treat obesity. Novo Nordisk markets the treatment under the brand name Wegovy in the US.Price: 2.05, Change: +0.61, Percent Change: +42.36","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4539":"次新股","PRGS":"Progress Software Corporation","BK4097":"系统软件","LENZ":"Therapeutics","BK4139":"生物科技","RANI":"Rani Therapeutics Holdings"},"translate_title":"Rani Therapeutics披露口服肥胖治疗进展；盘前股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1,"RANI":0.9,"LENZ":1},"content_text":"Rani Therapeutics (RANI) said late Wednesday that new data from a preclinical study evaluating the oral delivery of semaglutide via the RaniPill, or RT-116, capsule demonstrated comparable \"bioavailability, pharmacokinetics, and weight loss to subcutaneous administration.\"The company said the new data adds to the \"growing body of evidence\" about RaniPill's potential to enable oral delivery of multiple obesity treatments. Shares jumped more than 42% in premarket activity Thursday.The company plans to undertake a phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist. The obesity trial will begin this year in partnership with ProGen.Rani said semaglutide is currently only available as a subcutaneous injection to treat obesity. Novo Nordisk markets the treatment under the brand name Wegovy in the US.Price: 2.05, Change: +0.61, Percent Change: +42.36","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}